4-[(4-tert-butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carboxylic acid ethyl ester | 292070-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[(4-tert-butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carboxylic acid ethyl ester
• 英文别名: ethyl-1-methyl-4-[((4-tert-butoxycarbonyl)amino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1H-imidazole-2-carboxylate；4-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid ethyl ester；ethyl 1-methyl-4-[[1-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]imidazole-2-carbonyl]amino]imidazole-2-carboxylate
• CAS: 292070-63-4
• 化学式: C₁₇H₂₄N₆O₅
• 分子量: 392.415
• InChiKey: WVOGPVRCFSWXBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[(4-tert-butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carboxylic acid ethyl ester 在 盐酸 、 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 193.0h， 生成 (11aS)-8-(3-{5-[2-(2-ethoxycarbonyl-1-methyl-1H-imidazol-4-ylcarbamoyl)-1-methyl-1H-imidazol-4-ylcarbamoyl]-1-methyl-1H-pyrrol-3-ylcarbamoyl}propoxy)-7-methoxy-5-oxo-11-(tetrahydropyran-2-yloxy)-2,3,11,11a-tetrahydro-1H,5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid allyl ester
  参考文献：
  名称：

  An Extended Pyrrolobenzodiazepine–Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site

  摘要：

  The binding of nuclear factor Y (NF-Y) to inverted CCAAT boxes (ICBs) within the promoter region of DNA topoisomerase II alpha results in control of cell differentiation and cell cycle progression. Thus, NF-Y inhibitory small molecules could be employed to inhibit the replication of cancer cells. A library of pyrrolobenzodiazepine (PBD) C8-conjugates consisting of one PBD unit attached to tri-heterocyclic polyamide fragments was designed and synthesized. The DNA-binding affinity and sequence selectivity of each compound were evaluated in DNA thermal denaturation and DNase I footprinting assays, and the ability to inhibit binding of NF-Y to ICB1 and ICB2 was studied using an electrophoretic mobility shift assay (EMSA). 3a was found to be a potent inhibitor of NF-Y binding, exhibiting a 10-fold selectivity for an ICB2 site compared to an ICB1-containing sequence, and showing low nanomolar cytotoxicity toward human tumor cell lines. Molecular modeling and computational studies have provided details of the covalent attachment process that leads to formation of the PBD-DNA adduct, and have allowed the preference of 3a for ICB2 to be rationalized.

  DOI：

  10.1021/jm4001852
• 作为产物：
  描述：

  1-甲基-4-硝基咪唑-2-羧酸乙酯 、 4-叔丁氧羰基氨基-1-甲基-1H-咪唑-2-甲酸 在 palladium 10% on activated carbon 氢气 、 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 乙醇 、 乙酸乙酯 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 5.5h， 以66%的产率得到4-[(4-tert-butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES
  [FR] MÉTALLOCOMPLEXES POLYAMIDES DE PYRROLE ET IMIDAZOLE SELECTIFS VIS-A-VIS DE SEQUENCES

  摘要：

  本发明涉及用于将治疗或诊断组靶向到多核苷酸的序列选择性化合物。更具体地说，本发明涉及将金属配合物（如金属药物和金属诊断试剂）的序列选择性靶向到多核苷酸。

  公开号：

  WO2005033077A1

文献信息

• Total Synthesis of Distamycin A and 2640 Analogues:  A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity
  作者：Dale L. Boger、Brian E. Fink、Michael P. Hedrick

  DOI：10.1021/ja994192d

  日期：2000.7.1

  solution-phase synthesis of distamycin A and its extension to the preparation of 2640 analogues are described. Thus, solution-phase synthesis techniques with reaction workup and purification employing acid/base liquid−liquid extractions were used in the multistep preparation of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogues providing intermediates and final products that

  描述了远霉素 A 的液相合成的发展及其对 2640 类似物制备的扩展。因此，采用酸/碱液-液萃取进行反应后处理和纯化的液相合成技术用于多步制备偏霉素 A（8 步，40% 总产率）和 2640 类似物的原型库，提供中间体和最终产品在常规反应规模上纯度≥95%。公开了一种简单、快速和高通量的 DNA 结合亲和力筛选的补充开发，该筛选基于来自预结合溴化乙锭置换的荧光损失，适用于评估对 DNA 均聚物或特定序列的相对或绝对结合亲和力。发夹寡核苷酸）。使用发夹寡核苷酸，
• Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease
  申请人：Howard Philip Wilson

  公开号：US20080214525A1

  公开（公告）日：2008-09-04

  A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R 2 is selected from —H, —OH, =0, ═CH 2 , —CN, —R, OR, halo, ═CH—R, O—SO 2 —R, CO 2 R and COR; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo, where R and R′ are independently selected from optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 10 and R 11 either together form a double bond, or are selected from H and YR Y , where Y is selected from O, S and NH and R is H or C 1-7 alkyl or H and SO x M, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and R E is C 1-4 alkyl. The compound is useful for the treatment of proliferative diseases.

  化合物的公式（I）；或其盐或溶剂化物，其中：虚线表示C2和C3之间的双键是可选的；R2选择自-H，-OH，=0，═CH2，-CN，-R，OR，卤基，═CH-R，O-SO2-R，CO2R和COR；R7选择自H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤基，其中R和R'独立选择自可选取代的C1-7烷基，C3-20杂环基和C5-20芳基基团；R10和R11要么一起形成双键，要么选择自H和YRY，其中Y选择自O，S和NH，R为H或C1-7烷基或H和SOxM，其中x为2或3，M为一价的药用可接受阳离子；每个X独立地是杂芳基基团；n为1至6；以及RE为C1-4烷基。该化合物可用于治疗增殖性疾病。
• Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes
  申请人：Jaramillo David

  公开号：US20070265240A1

  公开（公告）日：2007-11-15

  The present invention relates to sequence selective compounds for targeting therapeutic or diagnostic groups to polynucleotides. More particularly, the present invention relates to sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.

  本发明涉及用于将治疗或诊断药物组选择性地定向到多核苷酸的序列选择性化合物。更具体地，本发明涉及将金属配合物（如金属药物和金属诊断剂）的序列选择性定向到多核苷酸。
• Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
  申请人：Howard Philip Wilson

  公开号：US08637664B2

  公开（公告）日：2014-01-28

  A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R2 is selected from —H, —OH, =0, ═CH2, —CN, —R, OR, halo, ═CH—R, O—SO2—R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo, where R and R′ are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and YRY, where Y is selected from O, S and NH and R is H or C1-7 alkyl or H and SOxM, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and RE is C1-4 alkyl. The compound is useful for the treatment of proliferative diseases.

  化合物的式子（I）或其盐或溶剂化物，其中：虚线表示C2和C3之间的双键是可选的；R2从—H，—OH，=0，═CH2，—CN，—R，OR，卤素，═CH—R，O—SO2—R，CO2R和COR中选择；R7从H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤素中选择，其中R和R'分别从选择性取代的C1-7烷基，C3-20杂环基和C5-20芳基中独立选择；R10和R11要么一起形成双键，要么从H和YRY中选择，其中Y从O，S和NH中选择，R是H或C1-7烷基或H和SOxM，其中x为2或3，M是单价的药用可接受阳离子；每个X都是独立的杂芳基基团；n为1到6；RE是C1-4烷基。该化合物用于治疗增生性疾病。
• Novel C8-linked pyrrolobenzodiazepine (PBD)–heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box
  作者：Federico Brucoli、Rachel M. Hawkins、Colin H. James、Geoff Wells、Terence C. Jenkins、Tom Ellis、John A. Hartley、Philip W. Howard、David E. Thurston

  DOI：10.1016/j.bmcl.2011.04.054

  日期：2011.6

  A series of novel DNA-interactive C8-linked pyrrolobenzodiazepine (PBD)-heterocyclepolyamide conjugates has been synthesised to explore structure/sequence-selectivity relationships. One conjugate (2d) has a greater selectivity and DNA binding affinity for inverted CCAAT sequences within the Topoisomerase II alpha promoter than the known C8-bis-pyrrole PBD conjugate GWL-78 (1b). (C) 2011 Elsevier Ltd. All rights reserved.